» Articles » PMID: 11747420

Chemistry of Gene Silencing: the Mechanism of NAD+-dependent Deacetylation Reactions

Overview
Journal Biochemistry
Specialty Biochemistry
Date 2001 Dec 19
PMID 11747420
Citations 121
Authors
Affiliations
Soon will be listed here.
Abstract

The Sir2 enzyme family is responsible for a newly classified chemical reaction, NAD(+)-dependent protein deacetylation. New peptide substrates, the reaction mechanism, and the products of the acetyl transfer to NAD(+) are described for SIR2. The final products of SIR2 reactions are the deacetylated peptide and the 2' and 3' regioisomers of O-acetyl ADP ribose (AADPR), formed through an alpha-1'-acetyl ADP ribose intermediate and intramolecular transesterification reactions (2' --> 3'). The regioisomers, their anomeric forms, the interconversion rates, and the reaction equilibria were characterized by NMR, HPLC, 18O exchange, and MS methods. The mechanism of acetyl transfer to NAD(+) includes (1) ADP ribosylation of the peptide acyl oxygen to form a high-energy O-alkyl amidate intermediate, (2) attack of the 2'-OH group on the amidate to form a 1',2'-acyloxonium species, (3) hydrolysis to 2'-AADPR by the attack of water on the carbonyl carbon, and (4) an SIR2-independent transesterification equilibrating the 2'- and 3'-AADPRs. This mechanism is unprecedented in ADP-ribosyl transferase enzymology. The 2'- and 3'-AADPR products are candidate molecules for SIR2-initiated signaling pathways.

Citing Articles

SIRT5: a potential target for discovering bioactive natural products.

Xie Y, Cai N, Liu X, He L, Ma Y, Yan C J Nat Med. 2025; .

PMID: 39979670 DOI: 10.1007/s11418-024-01871-6.


induced SIRT1 and SIRT3 are crucial for maintaining the metabolic switch in bacteria and host for successful pathogenesis.

Hajra D, Rajmani R, Chaudhary A, Gupta S, Chakravortty D Elife. 2024; 13.

PMID: 39693143 PMC: 11655064. DOI: 10.7554/eLife.93125.


Targeting sirtuins for cancer therapy: epigenetics modifications and beyond.

Shen H, Qi X, Hu Y, Wang Y, Zhang J, Liu Z Theranostics. 2024; 14(17):6726-6767.

PMID: 39479446 PMC: 11519805. DOI: 10.7150/thno.100667.


Drugs Targeting Sirtuin 2 Exhibit Broad-Spectrum Anti-Infective Activity.

Shenk T, Kulp Iii J, Chiang L Pharmaceuticals (Basel). 2024; 17(10).

PMID: 39458938 PMC: 11510315. DOI: 10.3390/ph17101298.


Activation and inhibition of sirtuins: From bench to bedside.

Fiorentino F, Fabbrizi E, Mai A, Rotili D Med Res Rev. 2024; 45(2):484-560.

PMID: 39215785 PMC: 11796339. DOI: 10.1002/med.22076.